Literature DB >> 20646843

Enhancement of radiation response in osteosarcoma and rhabdomyosarcoma cell lines by histone deacetylase inhibition.

Claudia Blattmann1, Susanne Oertel, Volker Ehemann, Markus Thiemann, Peter E Huber, Marc Bischof, Olaf Witt, Hedwig E Deubzer, Andreas E Kulozik, Jürgen Debus, Klaus-J Weber.   

Abstract

PURPOSE: Histone deacetylase inhibitors (HDACIs) can enhance the sensitivity of cells to photon radiation treatment (XRT) by altering numerous molecular pathways. We investigated the effect of pan-HDACIs such as suberoylanilide hydroxamic acid (SAHA) on radiation response in two osteosarcoma (OS) and two rhabdomyosarcoma (RMS) cell lines. METHODS AND MATERIALS: Clonogenic survival, cell cycle analysis, and apoptosis were examined in OS (KHOS-24OS, SAOS2) and RMS (A-204, RD) cell lines treated with HDACI and HDACI plus XRT, respectively. Protein expression was investigated via immunoblot analysis, and cell cycle analysis and measurement of apoptosis were performed using flow cytometry.
RESULTS: SAHA induced an inhibition of cell proliferation and clonogenic survival in OS and RMS cell lines and led to a significant radiosensitization of all tumor cell lines. Other HDACI such as M344 and valproate showed similar effects as investigated in one OS cell line. Furthermore, SAHA significantly increased radiation-induced apoptosis in the OS cell lines, whereas in the RMS cell lines radiation-induced apoptosis was insignificant with and without SAHA. In all investigated sarcoma cell lines, SAHA attenuated radiation-induced DNA repair protein expression (Rad51, Ku80).
CONCLUSION: Our results show that HDACIs enhance radiation action in OS and RMS cell lines. Inhibition of DNA repair, as well as increased apoptosis induction after exposure to HDACIs, can be mechanisms of radiosensitization by HDACIs. Copyright (c) 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20646843     DOI: 10.1016/j.ijrobp.2010.03.010

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  51 in total

Review 1.  Progress in radiotherapy for pediatric sarcomas.

Authors:  Susan L McGovern; Anita Mahajan
Journal:  Curr Oncol Rep       Date:  2012-08       Impact factor: 5.075

2.  A phase 1 trial of Vorinostat in combination with concurrent chemoradiation therapy in the treatment of advanced staged head and neck squamous cell carcinoma.

Authors:  Theodoros N Teknos; J Grecula; A Agrawal; M O Old; E Ozer; R Carrau; S Kang; J Rocco; D Blakaj; V Diavolitsis; B Kumar; P Kumar; Q Pan; M Palettas; L Wei; R Baiocchi; P Savvides
Journal:  Invest New Drugs       Date:  2018-12-19       Impact factor: 3.850

Review 3.  Therapeutic applications of histone deacetylase inhibitors in sarcoma.

Authors:  Fan Tang; Edwin Choy; Chongqi Tu; Francis Hornicek; Zhenfeng Duan
Journal:  Cancer Treat Rev       Date:  2017-07-06       Impact factor: 12.111

4.  Radiosensitization by histone deacetylase inhibition in an osteosarcoma mouse model.

Authors:  C Blattmann; M Thiemann; A Stenzinger; A Christmann; E Roth; V Ehemann; J Debus; A E Kulozik; W Weichert; P E Huber; S Oertel; A Abdollahi
Journal:  Strahlenther Onkol       Date:  2013-06-27       Impact factor: 3.621

5.  Synergistic antitumor effect of suberoylanilide hydroxamic acid and cisplatin in osteosarcoma cells.

Authors:  Mengyi Hou; Zhenglan Huang; Sicheng Chen; Hao Wang; Tianyu Feng; Shujuan Yan; Yuxi Su; Guowei Zuo
Journal:  Oncol Lett       Date:  2018-07-27       Impact factor: 2.967

6.  HD-MB03 is a novel Group 3 medulloblastoma model demonstrating sensitivity to histone deacetylase inhibitor treatment.

Authors:  Till Milde; Marco Lodrini; Larissa Savelyeva; Andrey Korshunov; Marcel Kool; Lena M Brueckner; André S L M Antunes; Ina Oehme; Arnulf Pekrun; Stefan M Pfister; Andreas E Kulozik; Olaf Witt; Hedwig E Deubzer
Journal:  J Neurooncol       Date:  2012-10-06       Impact factor: 4.130

Review 7.  Epigenetic alterations in osteosarcoma: promising targets.

Authors:  Binghao Li; Zhaoming Ye
Journal:  Mol Biol Rep       Date:  2014-02-06       Impact factor: 2.316

8.  Valproic acid causes radiosensitivity of breast cancer cells via disrupting the DNA repair pathway.

Authors:  Yue Luo; Hui Wang; Xipeng Zhao; Chao Dong; Fengmei Zhang; Gang Guo; Gongshe Guo; Xiaowei Wang; Simon N Powell; Zhihui Feng
Journal:  Toxicol Res (Camb)       Date:  2016-02-18       Impact factor: 3.524

9.  Suberoylanilide hydroxamic acid affects γH2AX expression in osteosarcoma, atypical teratoid rhabdoid tumor and normal tissue cell lines after irradiation.

Authors:  C Blattmann; S Oertel; M Thiemann; K J Weber; P Schmezer; O Zelezny; R Lopez Perez; A E Kulozik; J Debus; V Ehemann
Journal:  Strahlenther Onkol       Date:  2012-01-18       Impact factor: 3.621

10.  CRIF1 as a potential target to improve the radiosensitivity of osteosarcoma.

Authors:  Qian Ran; Feng Jin; Yang Xiang; Lixin Xiang; Qiushi Wang; Fengjie Li; Li Chen; Yuan Zhang; Chun Wu; Luping Zhou; Yanni Xiao; Lili Chen; Jiang Wu; Jiang F Zhong; Shengwen Calvin Li; Zhongjun Li
Journal:  Proc Natl Acad Sci U S A       Date:  2019-09-23       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.